- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketMarket MoversStocksIndicesMutual FundsIPOQuarterly Results
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Aditya Birla Sun Life Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.31 | 1.88 |
NAV | ₹31.17 | ₹40.50 |
Fund Started | 20 Jun 2019 | 25 Jun 2018 |
Fund Size | ₹840.48 Cr | ₹5727.59 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
2.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.31
1.88
NAV
₹31.17
₹40.50
Fund Started
20 Jun 2019
25 Jun 2018
Fund Size
₹840.48 Cr
₹5727.59 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 8.76% | 19.08% |
3 Year | 22.35% | 28.73% |
5 Year | 18.98% | 23.98% |
1 Year
8.76%
19.08%
3 Year
22.35%
28.73%
5 Year
18.98%
23.98%
Holding Analysis
Equity | 98.42% | 96.45% |
Cash | 1.58% | 3.55% |
Equity
98.42%
96.45%
Cash
1.58%
3.55%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.69% |
Cipla Ltd. | 7.65% |
Apollo Hospitals Enterprise Ltd. | 7.32% |
Abbott India Ltd. | 6.92% |
Torrent Pharmaceuticals Ltd. | 5.41% |
Fortis Healthcare Ltd. | 4.99% |
Lupin Ltd. | 4.52% |
Ajanta Pharma Ltd. | 3.96% |
Aurobindo Pharma Ltd. | 3.66% |
Ipca Laboratories Ltd. | 3.64% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.23% |
Divi's Laboratories Ltd. | 8.95% |
Dr. Reddy's Laboratories Ltd. | 8.92% |
Cipla Ltd. | 7.75% |
Aurobindo Pharma Ltd. | 6.06% |
Biocon Ltd. | 5.02% |
Mankind Pharma Ltd. | 4.20% |
Alkem Laboratories Ltd. | 4.01% |
Lupin Ltd. | 3.79% |
Gland Pharma Ltd. | 3.57% |
Fund Manager
Name | Dhaval Joshi | Dharmesh Kakkad |
Start Date | 21 Nov 2022 | 23 Feb 2021 |
Name
Dhaval Joshi
Dharmesh Kakkad
Start Date
21 Nov 2022
23 Feb 2021
About Fund
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 20 Jun 2019 | 25 Jun 2018 |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
20 Jun 2019
25 Jun 2018